Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, Starboard Value
What activist hedge fund Starboard wants from Pfizer
Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO Jeff Smith.
Starboard Chief Criticizes Pfizer’s R&D Investments
Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and through mergers and acquisitions.
Starboard Value CEO Jeff Smith: Pfizer needs to do a better job disciplining itself on investments
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential for growth in Kenvue, and more.
Starboard Makes Its Case to Shake-Up Pfizer and Kenvue
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Pfizer has “significantly overpaid” for recent acquisitions: Starboard Value
Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance on the pharma giant. Read more here.
1d
on MSN
Kenvue needs to fix its skin, health & beauty segments, Starboard's Jeff Smith says (update)
Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder and CEO of activist ...
pharmaphorum
1d
Starboard spells out its concerns with Pfizer's direction
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
FiercePharma
1d
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
2d
on MSN
Tylenol Maker Kenvue Stock Surges on Report Starboard Takes 'Sizable Stake'
Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.
1d
Starboard calls for Pfizer board to ‘hold management accountable’
Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...
1d
Starboard Focused on Kenvue's Struggling Unit
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
BioSpace
1d
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
FiercePharma
2d
Activist investor Starboard sets its sights on J&J spinout Kenvue: WSJ
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
1d
Starboard urges Pfizer board to ‘hold management accountable’, FT reports
Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback